nsc-262266 and Adenocarcinoma

DABIS maleate is an alkylating quaternary nitrogen. In a phase I study DABIS maleate was administered as a single intravenous infusion once every 3 weeks. 32 patients with solid tumours were studied, at least 3 per dose level (50-1400 mg/m2). Dose-limiting toxicity was severe paresthaesias in the face, around the mouth and in the tongue. Cerebellar ataxia developed at 750 mg/m2 or higher. Haematological toxicity was minimal. Nausea and vomiting were mild to moderate. No other non-haematological side-effects were noted. The recommended dose for phase II studies at once every 3 weeks is 750 mg/m2 intravenously as a 15 min infusion.

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cerebellar Ataxia; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Middle Aged; Paresthesia; Quaternary Ammonium Compounds